title: [Is the LHRH Agonist Recommended for Fertility Preservation ?].
abstract: The POEMS reportedan effect of goserelin for fertility preservation. The Clinical Practice Guideline for Breast Cancer by The Japanese Breast Cancer Society indicates that the use of the LHRH agonist (LHRHa) for preventing chemotherapy-induced early menopause is a grade C-1 recommendation, and its use for fertility preservation is a grade C-2 recommendation. Results from previous studies on the effects of LHRHa for fertility preservation have varied owing to differences in chemotherapy regimens, definitions of ovarian failure, and dosages of tamoxifen. In the POEMS, the primary endpoint of ovarian failure at 2 years was significantly lower, and the secondary endpoint of pregnancy outcomes was better in the combination group; however, precise interpretation is difficult because many cases were excluded. Currently, it is not necessary to revise The Clinical Practice Guideline; however, desirable results from future studies may allow the recommendation of a specific dosage of LHRHa for fertility preservation.
authors: Dept. of Breast Surgery, Osaka Medical College Hospital.
authors: Kosei
authors: K
authors: Kimura
authors: Mitsuhiko
authors: M
authors: Iwamoto
authors: Satoru
authors: S
authors: Tanaka
authors: Toru
authors: T
authors: Watanabe
authors: Tomohiko
authors: T
authors: Aihara
authors: Takeki
authors: T
authors: Sugimoto
authors: Kyuichiro
authors: K
authors: Miyara
authors: Mitsuhiro
authors: M
authors: Hayashi
authors: Tsutomu
authors: T
authors: Kouno
authors: Shinichi
authors: S
authors: Baba
authors: Hiroaki
authors: H
authors: Kawashima
authors: Naoki
authors: N
authors: Hashimoto
authors: Kazuhisa
authors: K
authors: Uchiyama
mesh_terms: D002986:Clinical Trials as Topic; D005260:Female; D059247:Fertility Preservation; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D017410:Practice Guidelines as Topic; D011247:Pregnancy
chemical_list: D007987:Gonadotropin-Releasing Hormone